The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
New schizophrenia drug Cobenfy offers hope with fewer side effects targeting symptoms more effectively than traditional ...
Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
The FDA approval of Bristol Myers Squibb's Cobenfy for schizophrenia could revolutionize treatment, but faces a competitive ...
The FDA has approved Cobenfy, the first new schizophrenia treatment in 30 years, offering a novel approach with fewer side ...
The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major ...
The US Food and Drug Administration has approved Cobenfy, also known as KarXT, a new schizophrenia treatment. The drug was ...
The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback